Shore Capital Reaffirms Hold Rating for GlaxoSmithKline plc (GSK)
Shore Capital reaffirmed their hold rating on shares of GlaxoSmithKline plc (LON:GSK) in a report published on Wednesday morning, Marketbeat.com reports.
A number of other analysts also recently issued reports on GSK. HSBC Holdings PLC reissued a buy rating and set a GBX 1,925 ($25.32) target price on shares of GlaxoSmithKline in a research report on Wednesday. Jefferies Group LLC lowered their price objective on shares of GlaxoSmithKline from GBX 1,540 ($20.26) to GBX 1,450 ($19.07) and set a buy rating for the company in a research report on Thursday, November 16th. Investec downgraded shares of GlaxoSmithKline to a hold rating and lowered their price objective for the company from GBX 1,800 ($23.67) to GBX 1,390 ($18.28) in a research report on Monday, November 6th. Societe Generale reissued a sell rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th. Finally, Citigroup Inc. restated a neutral rating on shares of GlaxoSmithKline in a research note on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. The company has an average rating of Hold and a consensus price target of GBX 1,586.67 ($20.87).
GlaxoSmithKline (GSK) opened at GBX 1,297.50 ($17.07) on Wednesday. GlaxoSmithKline has a 12 month low of GBX 1,291.50 ($16.99) and a 12 month high of GBX 1,724.50 ($22.68).
GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The firm had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%.
The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be issued a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a yield of 1.41%.
In related news, insider Urs Rohner acquired 473 shares of the company’s stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). Also, insider Simon Dingemans acquired 1,076 shares of the company’s stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average price of GBX 1,527 ($20.08) per share, with a total value of £16,430.52 ($21,610.57). Insiders purchased 1,576 shares of company stock valued at $2,400,376 in the last quarter.
TRADEMARK VIOLATION NOTICE: “Shore Capital Reaffirms Hold Rating for GlaxoSmithKline plc (GSK)” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/shore-capital-reaffirms-hold-rating-for-glaxosmithkline-plc-gsk/1726957.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.